Cocrystal Pharma 8-K: General Corporate Info, Nasdaq Listing Confirmed
Ticker: COCP · Form: 8-K · Filed: Jan 4, 2024 · CIK: 1412486
| Field | Detail |
|---|---|
| Company | Cocrystal Pharma, INC. (COCP) |
| Form Type | 8-K |
| Filed Date | Jan 4, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: regulatory-filing, corporate-governance, nasdaq-listing
TL;DR
**COCP filed a routine 8-K, confirming Nasdaq listing and regulatory compliance.**
AI Summary
Cocrystal Pharma, Inc. filed an 8-K on January 4, 2024, primarily to disclose general corporate information and confirm its common stock, trading under the symbol COCP, is registered on The Nasdaq Stock Market LLC. This filing, while not announcing new financial events, is important for investors as it reaffirms the company's compliance with SEC regulations and its continued listing on a major exchange, which is crucial for liquidity and investor confidence.
Why It Matters
This filing confirms Cocrystal Pharma's ongoing compliance and Nasdaq listing, which is fundamental for the stock's trading and investor trust.
Risk Assessment
Risk Level: low — This is a routine administrative filing with no new material financial or operational disclosures that would introduce significant risk.
Analyst Insight
A smart investor would note this filing as a routine compliance update, confirming the company's continued listing on Nasdaq, but would not expect any immediate stock price movement based solely on this information. Further research into the company's financials and drug pipeline would be necessary for investment decisions.
Key Players & Entities
- Cocrystal Pharma, Inc. (company) — the registrant filing the 8-K
- The Nasdaq Stock Market LLC (company) — the exchange where Cocrystal Pharma's common stock is registered
- COCP (other) — the trading symbol for Cocrystal Pharma's common stock
- January 4, 2024 (date) — the date of the earliest event reported and the filing date
FAQ
What is the primary purpose of this 8-K filing by Cocrystal Pharma, Inc.?
The primary purpose of this 8-K filing by Cocrystal Pharma, Inc. is to provide general corporate information, including its registration on The Nasdaq Stock Market LLC under the trading symbol COCP, and to satisfy Regulation FD Disclosure requirements, as indicated by 'ITEM INFORMATION: Regulation FD Disclosure'.
On what date was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 4, 2024, as stated under 'Date of Report (Date of earliest event reported): January 4, 2024'.
What is the trading symbol and the exchange where Cocrystal Pharma, Inc.'s common stock is registered?
Cocrystal Pharma, Inc.'s common stock trades under the symbol COCP and is registered on The Nasdaq Stock Market LLC (The Nasdaq Capital Market), as detailed under 'Securities registered pursuant to Section 12(b) of the Act'.
What is Cocrystal Pharma, Inc.'s business address and phone number?
Cocrystal Pharma, Inc.'s business address is 19805 N. Creek Parkway, Bothell, WA 98011, and its telephone number is (877) 262-7123, according to the filing.
Has Cocrystal Pharma, Inc. had any previous names, and if so, what were they and when did the name changes occur?
Yes, Cocrystal Pharma, Inc. previously operated under the names BIOZONE PHARMACEUTICALS, INC. (name changed on 20110304) and International Surf Resorts, Inc. (name changed on 20070917), as listed under 'FORMER COMPANY' information in the filing.
Filing Stats: 452 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-01-04 16:01:43
Filing Documents
- form8-k.htm (8-K) — 37KB
- ex99-1.htm (EX-99.1) — 18KB
- ex99-1_001.jpg (GRAPHIC) — 17KB
- 0001493152-24-001074.txt ( ) — 251KB
- cocp-20240104.xsd (EX-101.SCH) — 3KB
- cocp-20240104_lab.xml (EX-101.LAB) — 33KB
- cocp-20240104_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 4, 2024 Cocrystal Pharma, Inc. By: /s/ James Martin Name: James Martin Title: Chief Financial Officer and Co-Chief Executive Officer